查看購物車
  • English
封面
市場調查報告書
商品編碼
1914722

動物用藥品市場－全球產業規模、佔有率、趨勢、機會及預測（依產品類型、動物種類、感染疾病類型、最終用戶、通路、地區及競爭格局分類，2021-2031年）

Animal Pharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Animal Type, By Type of Infection, By End User, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球動物用藥品市場預計將從2025年的280.1億美元成長到2031年的397.6億美元，複合年成長率（CAGR）為6.01%。該市場涵蓋動物醫藥、疫苗和藥用飼料添加劑的研發和銷售，用於治療和預防牲畜和通用動物的感染疾病。推動市場成長的關鍵因素包括全球對糧食安全日益成長的需求（這需要高效的畜牧管理）以及控制人畜共通病原體的迫切需求。此外，寵物飼主與其寵物之間日益深厚的情感紐帶也顯著推動了獸醫支出。根據澳洲動物藥品協會（Animal Medicines Australia）的報告，預計到2025年，該地區擁有寵物的家庭數量將達到3,160萬戶，其中73%的家庭擁有寵物，這凸顯了支撐該行業的龐大消費群。

市場概覽
預測期 2027-2031
市場規模：2025年 280.1億美元
市場規模：2031年 397.6億美元
複合年成長率：2026-2031年 6.01%
成長最快的細分市場 疫苗
最大的市場 北美洲

然而，日益嚴格的抗菌素抗藥性監管為市場擴張帶來了重大障礙。各國政府和國際衛生組織為保護公眾健康，正在實施更嚴格的畜牧業抗生素使用規定，這為製藥公司創造了必須遵守的嚴苛監管環境。這種環境限制了傳統抗菌產品的市場競爭力，迫使生產者投入大量成本用於產品配方改良或開發替代療法。因此，這些合規要求以及對非抗生素解決方案創新的需求，對全球市場的商業性發展構成了重大阻礙。

市場促進因素

為滿足全球日益成長的動物性蛋白質需求，畜牧業生產集約化程度不斷提高，這是推動產業成長的主要因素。向高密度工業化生產模式的轉變，雖然提高了生產效率，但也使牲畜更容易感染疾病，因此需要嚴格的管理通訊協定，包括疫苗接種、驅蟲和使用含藥飼料添加劑。依賴這些藥物解決方案對於維護動物健康和滿足國際食品安​​全標準至關重要。根據聯合國糧食及農業組織（糧農組織）2024年6月發布的《糧食展望－世界糧食市場雙年報告》，預計2024年全球肉類產量將達到3.71億噸，這一規模凸顯了藥物保護對於防止疾病爆發造成經濟損失的必要性。

同時，寵物人性化的趨勢以及由此帶來的醫療保健支出成長正在改變市場格局。飼主越來越將寵物視為家庭成員，並願意為癌症和皮膚病等先進治療支付更多費用，而不僅限於基礎護理。寵物保險的日益普及進一步推動了這一轉變，寵物保險可以涵蓋高昂的獸醫費用。根據北美寵物健康保險協會於2024年5月發布的《2024年產業趨勢報告》，2023年美國寵物保險保費總額達39億美元。在這些因素的共同推動下，該產業的蓬勃發展也體現在Zootis公司發布的2024年報告中，該公司宣布2023會計年度全年營收達85億美元。

市場挑戰

針對抗菌素抗藥性的監管力道不斷加大，已成為全球動物用藥品市場成長的一大障礙。國際衛生組織和各國政府實施的嚴格法規直接限制了抗生素產品組合的商業性成功，而抗生素產品組合歷來是動物醫藥公司穩定的收入來源。這種嚴苛的法規結構迫使生產商投入巨資重新配製現有產品，以消除促進生長的宣傳並滿足日益嚴格的監測要求，從而擠佔了原本可用於拓展市場的資金。

這些法規的實際結果是全球抗菌藥物銷售量大幅下降，因為企業被迫減少對這類藥物的依賴。 2024年，動物健康組織（Health for Animals）報告稱，其成員公司2015年至2022年間的全球抗生素銷售額下降了29.9%，顯示該行業正經歷結構性衰退。這種監管壓力有效地限制了該治療領域的成長前景，迫使整個產業進行高成本且複雜的轉型，轉向預防性醫療保健措施，而不是依賴現有產品線的持續商業性成功。

市場趨勢

物種特異性單株抗體（mAb）的商業性應用正在從根本上改變治療格局，為骨關節炎和皮膚病等慢性疾病提供標靶性強、毒性低的解決方案。與傳統化學藥物不同，這些生物製藥透過精準的作用機制發揮作用，從而減少全身性副作用，這迫使生產商對專用基礎設施進行大量投資，以滿足日益成長的臨床需求。這種向生物製藥生產的結構性轉變體現在重要的供應方舉措中。例如，禮來動物保健公司（Elanco Animal Health）在其2024年8月的新聞稿「禮來投資1.3億美元擴大單株抗體生產」中宣布，將撥款1.3億美元擴建其位於堪薩斯州的工廠，以增強其單株抗體的生產能力。這項投資凸顯了該產業正穩步從廣譜頻譜轉向先進的物種特異性治療方法。

同時，獸醫遠距醫療與數位藥局服務的整合正在改變動物用藥品的處方、購買和配送方式。這一趨勢將虛擬醫療平台與自動化電商物流相結合，形成一個無縫循環，不僅提高了用藥依從性，也為數位領域的領導企業創造了持續的收入。這種自動化採購模式的優勢在近期的財務表現中得到了充分體現。 Chewy公司在2024年3月發布的「2023會計年度致股東信」中報告稱，其2023會計年度的自動續訂銷售額達到84.9億美元，佔總淨銷售額的76%以上。這一規模反映了消費者購買習慣的永久性結構性轉變，即從一次性的診所交易轉向便利的訂閱式數位醫療解決方案。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球動物用藥品市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（藥品、疫苗、藥用飼料）
    • 依動物類型（伴侶動物、家畜）
    • 依給藥途徑（口服、注射、局部）
    • 依感染類型（病毒性、細菌性、寄生蟲性、其他）分類
    • 依最終使用者（獸醫院、動物診所、照護現場/院內檢測、其他）
    • 按分銷管道（獸醫診所、藥局/藥局、電子商務）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美動物用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲動物用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章 亞太動物用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲動物用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美動物用藥品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球動物用藥品市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • CH Boehringer Sohn AG & Co. KG
  • Merck & Co., Inc
  • Ceva Sante Animale SA,
  • Vetoquinol SA
  • Bayer AG
  • Virbac SA
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4543

The Global Animal Pharmaceuticals Market is projected to expand from USD 28.01 Billion in 2025 to USD 39.76 Billion by 2031, registering a CAGR of 6.01%. This market covers the research, development, and sale of veterinary medications, vaccines, and medicated feed additives designed to treat and prevent diseases in both livestock and companion animals. Growth is largely fueled by the rising global demand for food security, which necessitates efficient livestock management, and the increasing need to control zoonotic pathogens. Furthermore, the strengthening emotional connection between pet owners and their animals significantly boosts spending on veterinary care. As reported by Animal Medicines Australia, the pet population in that region reached an estimated 31.6 million in 2025, with 73% of households owning a pet, underscoring the vast consumer base supporting the industry.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 28.01 Billion
Market Size 2031USD 39.76 Billion
CAGR 2026-20316.01%
Fastest Growing SegmentVaccine
Largest MarketNorth America

Nevertheless, market expansion faces a major hurdle due to growing regulatory scrutiny concerning antimicrobial resistance. Governments and global health bodies are implementing stricter rules on antibiotic use in livestock to protect public health, creating a rigorous regulatory landscape that pharmaceutical companies must navigate. This environment limits the sales potential of traditional antimicrobial products and forces manufacturers to bear significant costs for reformulating products and developing alternative therapies. Consequently, these compliance demands and the need for innovation in non-antibiotic solutions create substantial barriers to the seamless commercial progression of the global market.

Market Driver

The push for intensified livestock production to satisfy the growing global appetite for animal protein serves as a primary catalyst for industry growth. As farming shifts toward high-density industrial models to optimize output, herds become more vulnerable to infectious diseases, requiring rigorous protocols involving vaccines, parasiticides, and medicated feed additives. This dependence on pharmaceutical solutions is essential for maintaining animal health and adhering to international food safety standards. According to the Food and Agriculture Organization's 'Food Outlook - Biannual Report on Global Food Markets' from June 2024, global meat production is predicted to reach 371 million tonnes in 2024, a scale that highlights the necessity of pharmaceutical protection to prevent economic losses caused by disease outbreaks.

Concurrently, the market is being transformed by the trend of pet humanization and the resulting increase in healthcare spending. Pet owners increasingly regard their animals as family members, leading to a greater willingness to pay for sophisticated treatments in areas like oncology and dermatology, moving beyond mere basic care. This transition is further bolstered by the rising utilization of pet insurance, which helps offset the costs of high-value veterinary procedures. As stated by the North American Pet Health Insurance Association in its 'State of the Industry Report 2024' released in May 2024, total pet insurance premiums in the U.S. hit $3.9 billion in 2023. The sector's financial vitality, driven by these combined factors, is reflected in Zoetis Inc.'s 2024 report, which announced a full-year revenue of $8.5 billion for the fiscal year 2023.

Market Challenge

Heightened regulatory attention regarding antimicrobial resistance poses a significant obstacle to the growth of the Global Animal Pharmaceuticals Market. International health authorities and governments are applying rigorous controls that directly constrain the commercial success of antibiotic portfolios, which have traditionally provided steady revenue for veterinary pharmaceutical firms. This strict regulatory framework compels manufacturers to invest heavily in reformulating existing products to eliminate growth-promotion claims and to meet enhanced surveillance mandates, diverting financial resources that could otherwise be used to fuel broader market expansion.

The practical consequence of these restrictions is a notable decrease in the global sales volume of antimicrobial agents, as companies are forced to decrease their dependence on these drug classes. According to HealthforAnimals, the association reported in 2024 that global antibiotic sales among its members fell by 29.9% between 2015 and 2022, signaling a structural decline in this segment. This regulatory pressure effectively limits the growth prospects of therapeutic drug categories, necessitating a costly and complicated industry shift toward preventative healthcare measures rather than relying on the continued commercial success of established product lines.

Market Trends

The widespread commercial adoption of species-specific monoclonal antibodies (mAbs) is radically changing the treatment landscape by offering targeted, low-toxicity solutions for chronic ailments like osteoarthritis and skin conditions. Unlike conventional chemical medications, these biologics function through precise mechanisms that reduce systemic side effects, driving manufacturers to invest significantly in specialized infrastructure to handle rising clinical needs. This structural move toward biological manufacturing is illustrated by major supply-side initiatives; for instance, Elanco Animal Health Incorporated announced in an August 2024 press release, 'Elanco Invests $130 Million in Expansion to Boost Monoclonal Antibody Production,' that it is allocating $130 million to expand its Kansas facility specifically to advance its monoclonal antibody capabilities. This investment underscores the industry's definitive shift from broad-spectrum drugs to advanced, species-specific biological therapies.

At the same time, the integration of veterinary telehealth with digital pharmacy services is transforming how animal health products are prescribed, bought, and supplied. This trend merges virtual care platforms with automated e-commerce fulfillment, establishing a seamless cycle that improves medication adherence and secures recurring revenue for digital leaders. The strength of these automated procurement models is clear in recent financial results; Chewy, Inc. noted in its 'Fiscal Year 2023 Letter to Shareholders' in March 2024 that Autoship sales hit $8.49 billion for fiscal year 2023, accounting for over 76% of total net sales. Such volume reflects a permanent structural shift in consumer purchasing habits, moving away from sporadic in-clinic transactions toward convenient, subscription-based digital health solutions.

Key Market Players

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • C.H. Boehringer Sohn AG & Co. KG
  • Merck & Co., Inc
  • Ceva Sante Animale S.A.,
  • Vetoquinol S.A.
  • Bayer AG
  • Virbac SA
  • Phibro Animal Health Corporation
  • Dechra Pharmaceuticals plc

Report Scope

In this report, the Global Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Pharmaceuticals Market, By Product Type

  • Drugs
  • Vaccine
  • Medicated Feed

Animal Pharmaceuticals Market, By Animal Type

  • Companion Animal
  • Livestock Animal

Animal Pharmaceuticals Market, By Route of Administration

  • Oral
  • Parenteral
  • Topical

Animal Pharmaceuticals Market, By Type of Infection

  • Viral
  • Bacterial
  • Parasitic
  • Others

Animal Pharmaceuticals Market, By End User

  • Veterinary Hospitals
  • Veterinary Clinics
  • Point of care/In-house testing
  • Others

Animal Pharmaceuticals Market, By Distribution Channel

  • Veterinary Hospitals
  • Pharmacies and Drug stores
  • E-commerce

Animal Pharmaceuticals Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Pharmaceuticals Market.

Available Customizations:

Global Animal Pharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Pharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Drugs, Vaccine, Medicated Feed)
    • 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
    • 5.2.4. By Type of Infection (Viral, Bacterial, Parasitic, Others)
    • 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Point of care/In-house testing, Others)
    • 5.2.6. By Distribution Channel (Veterinary Hospitals, Pharmacies and Drug stores, E-commerce)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Animal Pharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Animal Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Type of Infection
    • 6.2.5. By End User
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Animal Pharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Animal Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Type of Infection
        • 6.3.1.2.5. By End User
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Canada Animal Pharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Animal Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Type of Infection
        • 6.3.2.2.5. By End User
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Mexico Animal Pharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Animal Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Type of Infection
        • 6.3.3.2.5. By End User
        • 6.3.3.2.6. By Distribution Channel

7. Europe Animal Pharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Animal Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Type of Infection
    • 7.2.5. By End User
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Animal Pharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Animal Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Type of Infection
        • 7.3.1.2.5. By End User
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. France Animal Pharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Animal Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Type of Infection
        • 7.3.2.2.5. By End User
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. United Kingdom Animal Pharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Animal Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Type of Infection
        • 7.3.3.2.5. By End User
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. Italy Animal Pharmaceuticals Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Animal Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Type of Infection
        • 7.3.4.2.5. By End User
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Animal Pharmaceuticals Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Animal Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Type of Infection
        • 7.3.5.2.5. By End User
        • 7.3.5.2.6. By Distribution Channel

8. Asia Pacific Animal Pharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Animal Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Type of Infection
    • 8.2.5. By End User
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Animal Pharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Animal Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Type of Infection
        • 8.3.1.2.5. By End User
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. India Animal Pharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Animal Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Type of Infection
        • 8.3.2.2.5. By End User
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. Japan Animal Pharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Animal Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Type of Infection
        • 8.3.3.2.5. By End User
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. South Korea Animal Pharmaceuticals Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Animal Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Type of Infection
        • 8.3.4.2.5. By End User
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Animal Pharmaceuticals Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Animal Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Type of Infection
        • 8.3.5.2.5. By End User
        • 8.3.5.2.6. By Distribution Channel

9. Middle East & Africa Animal Pharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Animal Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Type of Infection
    • 9.2.5. By End User
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Animal Pharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Animal Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Type of Infection
        • 9.3.1.2.5. By End User
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. UAE Animal Pharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Animal Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Type of Infection
        • 9.3.2.2.5. By End User
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. South Africa Animal Pharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Animal Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Type of Infection
        • 9.3.3.2.5. By End User
        • 9.3.3.2.6. By Distribution Channel

10. South America Animal Pharmaceuticals Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Animal Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Type of Infection
    • 10.2.5. By End User
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Animal Pharmaceuticals Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Animal Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Type of Infection
        • 10.3.1.2.5. By End User
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Colombia Animal Pharmaceuticals Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Animal Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Type of Infection
        • 10.3.2.2.5. By End User
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. Argentina Animal Pharmaceuticals Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Animal Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Type of Infection
        • 10.3.3.2.5. By End User
        • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Animal Pharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Elanco Animal Health Incorporated
  • 15.3. C.H. Boehringer Sohn AG & Co. KG
  • 15.4. Merck & Co., Inc
  • 15.5. Ceva Sante Animale S.A.,
  • 15.6. Vetoquinol S.A.
  • 15.7. Bayer AG
  • 15.8. Virbac SA
  • 15.9. Phibro Animal Health Corporation
  • 15.10. Dechra Pharmaceuticals plc

16. Strategic Recommendations

17. About Us & Disclaimer